All In Biotech

NDA 212479 · Shorla

Jylamvo

Methotrexate · Oral · Folate Analog Metabolic Inhibitor

Last checked: Nov 20, 2026Latest source record: May 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Nov 29, 2022

Approved uses

6

Original approval plus efficacy supplements

Registered trials

2,087

570 Phase 3, 211 recruiting

FAERS reports

415,539

315,071 serious, 34,392 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: EMBRYO-FETAL TOXICITY, HYPERSENSITIVITY REACTIONS and SEVERE ADVERSE REACTIONS Methotrexate can cause embryo-fetal toxicity, including fetal death. For non-neoplastic diseases, Jylamvo is contraindicated in pregnancy. For neoplastic diseases, advise females and males of reproductive potential to use effective contraception during and after treatment with Jylamvo [see Contraindications (4) , Warnings and Precautions (5.1) , Use in Specific Populations (8.1 , 8.3) ] . Jylamvo is contraindicated in patients with a history of severe hypersensitivity reactions to methotrexate, including anaphylaxis [ Contraindications (4) , Warnings and Precautions (5.2) ] . Serious adverse reactions, including death, have been reported with methotrexate. Closely monitor for infections and adverse reactions of the bone marrow, gastrointestinal tract, liver, lungs, skin, and kidneys. Withhold or...

What it is approved for

From the label in effect Nov 5, 2026.

JYLAMVO is a folate analog metabolic inhibitor indicated for the: Treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen ( 1.1 ) Treatment of adults with mycosis fungoides ( 1.1 ) Treatment of adults with relapsed or refractory non-Hodgkin lymphoma as part of a metronomic combination regimen ( 1.1 ) Treatment of adults with rheumatoid arthritis ( 1.2 ) Treatment of pediatric patients with polyarticular juvenile idiopathic arthritis (pJIA) ( 1.3 ) Treatment of adults with severe psoriasis (1.4 ) 1.1 Neoplastic Diseases JYLAMVO is indicated for the: treatment of adults and pediatric patients with acute lymphoblastic leukemia (ALL) as part of a combination chemotherapy maintenance regimen. treatment of adults with mycosis fungoides (cutaneous T-cell lymphoma) as a single agent or as part of a combination chemotherapy regimen. treatment of adults with relapsed or refractory non-Hodgkin lymphomas as part of a metronomic combination chemotherapy regimen. 1.2 Rheumatoid Arthritis JYLAMVO is indicated for the treatment of adults with rheumatoid arthritis. 1.3 Polyarticular Juvenile Idiopathic Arthritis JYLAMVO is indicated for the treatment of pediatric patients with polyarticular Juvenile Idiopathic Arthritis (pJIA). 1.4 Psoriasis JYLAMVO is indicated for the treatment of adults with severe psoriasis.

Mechanism: Methotrexate inhibits dihydrofolic acid reductase. Dihydrofolates must be reduced to tetrahydrofolates by this enzyme before they can be utilized as carriers of one-carbon groups in the synthesis of purine nucleotides and thymidylate. Therefore, methotrexate interferes with DNA synthesis, repair, and cellular replication. Actively proliferating tissues such as malignant cells, bone marrow, fetal cells, buccal and intestinal mucosa, and cells of the urinary bladder are in general more sensitive to this effect of methotrexate. The mechanism of action in rheumatoid arthritis and in psoriasis is...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • JYLAMVO · METHOTREXATE 2MG/ML · SOLUTION, ORAL · Prescription
  • JYLAMVO · METHOTREXATE 2MG/ML · SOLUTION, ORAL · Prescription
  • JYLAMVO · METHOTREXATE 2MG/ML · SOLUTION, ORAL · Prescription
  • JYLAMVO · METHOTREXATE 2MG/ML · SOLUTION, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Methotrexate" as an intervention, any sponsor and status, largest first.

All 2,087 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective75,829
  • rheumatoid arthritis38,595
  • arthralgia36,779
  • pain35,908
  • off label use35,260
  • fatigue29,599
  • nausea24,357
  • joint swelling22,621
  • headache21,284
  • rash20,346
  • condition aggravated20,228
  • drug intolerance20,017

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20045,129
20055,083
20064,969
20077,782
20088,995
20099,160
20109,678
201110,610
201214,953
201316,975
201416,960
201520,301
201621,746
201722,399
201831,886
201932,098
202039,615
202126,415
202229,157
202326,797
202423,073
202520,032
202611,717

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 7,151 on PubMed

Sponsor: Shorla

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.